Trial Profile

Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Effectiveness (Immunogenicity) and Safety of GC1107 Administered Intramuscularly in Healthy Adults

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 15 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GC 1107 (Primary) ; Diphtheria-tetanus vaccine
Indications Diphtheria; Tetanus
Focus Registrational; Therapeutic Use
Sponsors GC Pharma; Green Cross

Most Recent Events

28 Jan 2019 Primary endpoint has been met. (seroprotection rate of diphtheria and tetanus)
28 Jan 2019 Results published in the Journal of Korean Medical Science
02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com